EHEC Vaccine Antigen Selection Using In Silico Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against Enterohemorrhagic Escherichia coli (EHEC) O157:H7 are limited, and there is a need for more effective antigens to prevent colonization and infection, as existing vaccines focus mainly on known virulence factors and do not fully address the complex molecular and cellular processes involved in EHEC infection.
Innovation Solution
A genome-wide in silico search identifies EHEC-specific antigens with high probability of exposure during infection, which are grouped by antigenicity and tested as DNA vaccines in a murine model to induce immune responses and reduce bacterial colonization, using immunoinformatics to prioritize candidates and formulate them with adjuvants for enhanced immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If existing vaccines focus on known virulence factors, then vaccine development is simplified, but immune protection is insufficient against complex EHEC infection processes
Solution Approach 1:
The vaccine composition is segmented into multiple distinct antigenic components including LomW outer membrane protein, EscJ lipoprotein, EscC secretion system protein, and intimin adhesin. Each antigen targets a specific stage or mechanism of EHEC pathogenesis, collectively providing comprehensive protection against the complex infection process while maintaining manageable development through modular antigen selection
Solution Approach 2:
The vaccine employs a composite antigen formulation combining proteins from different EHEC virulence mechanisms (prophage-derived LomW, T3SS components EscJ and EscC, and adhesin intimin). This composite approach integrates multiple protective functions into a single vaccine composition, addressing the complexity of EHEC infection while streamlining delivery and manufacturing
2Quantity of substance
If genome-wide in silico search is performed to identify EHEC-specific antigens, then antigen discovery comprehensiveness is improved, but analysis complexity and time increase
Solution Approach 1:
The patent applies preliminary bioinformatics filtering criteria including signal peptide prediction, transmembrane domain analysis, and subcellular localization prediction to narrow down the genome-wide antigen candidate list before experimental validation. This preliminary action reduces the complexity of subsequent analysis while maintaining comprehensive antigen discovery
Solution Approach 2:
The patent replaces extensive wet-lab screening of all possible antigens with in silico prediction algorithms and immunoinformatics approaches. This substitution of computational methods for experimental methods efficiently identifies high-priority antigen candidates, increasing candidate diversity while reducing overall analysis complexity and time
3Adaptability or versatility
If multiple EHEC antigens are combined in vaccine composition, then immune response coverage is enhanced, but formulation complexity increases
Solution Approach 1:
The vaccine formulation achieves universality by selecting antigens that target multiple critical functions of EHEC pathogenesis: LomW for outer membrane integrity, EscJ and EscC for secretion system function, and intimin for adherence. This multi-functional antigen selection provides broad immune coverage while maintaining a manageable four-component formulation that avoids excessive complexity
Data Source
AI summary
Certain embodiments are directed to compositions comprising EHEC-specific antigens. In certain aspects EHEC O157:H7-specific antigen(s) are used as components of immunogenic compositions and vaccines.